N/A
Completed N=45
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Source: ClinicalTrials.gov NCT00539253 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Sep 2017
Primary outcomePrimary: Nodule Size — 6.4 centimeters
Summary
This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Nodule Size |
6.4 | — |
| PRIMARY Nodule Enhancement |
32.8 | — |
Eligibility Criteria
Inclusion Criteria
- Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE.
- International Normalized Ratio (INR) 80,000
Exclusion Criteria
- Contraindications to TACE procedure
- Unable to have an MRI Scan
- Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol
- Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
- Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders
- Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate<15cc/min)
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT00539253). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.